Cytokinetics Inc vs Valero Energy Corporation — how do they compare? Cytokinetics Inc trades at $76.44 (market cap $10.63B), while Valero Energy Corporation trades at $328 (market cap $93.27B). The key difference: Valero Energy Corporation is far larger — about 8.8× Cytokinetics Inc's market cap, and Valero Energy Corporation pays a 1.48% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | VLO | |
|---|---|---|
Market Cap | $10.63B | $93.27B |
Sector | Technology | Energy |
52-Week High | $87.26 | $323.92 |
52-Week Low | $34.31 | $133.38 |
Enterprise Value | $10.74B | $96.74B |
Dividend Yield | — | 1.48% |
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Valero Energy (VLO) trades at $314.95, up 5.58% in 24 hours, reflecting strong momentum. The stock exhibits bullish technical signals with key support at $307 and resistance at $324. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $12.54 surpassing the $10.11 estimate. Revenue for 2026 is projected to rise to $139.4 billion, with net income margin improving to 5.17%.
Outlook remains positive due to robust refining margins and renewable diesel growth, but risks include volatile oil prices and geopolitical tensions. Analysts maintain a buy consensus with a $324.27 price target, indicating potential upside. Investors should monitor execution on earnings guidance and global energy supply dynamics.
Trailing returns across standard periods
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →